ProQR Therapeutics NV expected to post a loss of 12 cents a share - Earnings Preview

ProQR Therapeutics NV

30/07/2024 19:55

* ProQR Therapeutics NV  PRQR.OQ   PRQR.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 1
(estimated) for the period ending June 30 2024
    * The Leiden Zuid-holland-based  company is expected to
report a
822.4% increase in revenue to €11.456 million from €1.24 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for ProQR Therapeutics NV is
for a
loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $5.00​, above​ its last closing price
of $1.81. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.12       -0.11      -0.09     Beat    17.8
 Dec. 31 0001  -0.10       0.01       -0.07     Missed  -745.2
 Sep. 30 2023  -0.10       -0.09      -0.07     Beat    17.8​
 Jun. 30 2023  -0.11       -0.11      -0.10     Beat    10
 ​​Mar.        -0.09       -0.12      -0.11     Beat    6.5
 31 2023                                                
 Dec. 31 2022  -0.17       -0.18      -0.16     Beat    10.4​
 Jan. 1 0001   -0.19       -0.21      -0.34     Missed  -61.5
 Jun. 30 2022  -0.22       -0.22      -0.21     Beat    2.7
 This summary was machine generated July 30 at 18:55 GMT.  All
figures in euros unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)